UK Life Science Trend Analysis 2024

Press release

Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development

• Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer mouse model systems

• The collaboration will combine advanced in vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology for precision oncology medicines

Sandwich, Kent, UK / 18th June 2024 / Discovery Park, Kent’s thriving life science and innovation community, is preparing to welcome 300 healthcare innovators to its campus on Thursday 20th June for its second annual Innovation Summit, with only final spots remaining.

This year’s summit has a focus on innovation in healthcare, taking a close look at trends in healthy ageing, breakthroughs in medicine and life science, and the role of digital collaboration in future healthcare delivery.

On Wednesday 15th May, Pharmaron hosted the 3rd Chemistry for Life Science Symposium. Academic and industry experts presented on the leading edge of drug discovery and process chemistry with speakers Professor Robert Phipps (University of Cambridge), Professor Ross Denton (University of Nottingham), Dr Sarah Skerratt (CHARM Therapeutics), Dr David Wilson (AstraZeneca), Dr Jeremy Parker (AstraZeneca) along with Dr Sébastien Campos (Pharmaron) and Dr Aaron Dumas (Pharmaron).

Accelerating Drug Discovery with the CCDC, AWS, and Intel: Curated Data Set of Protein Structures from the Protein Data Bank with Predicted Hydrogen Positions Now Available

AMSBIO offers a range of kits, media and reagents enabling development of food in a way that is not wasteful of our natural resources and is not detrimental to the environment or consumer health.

Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development.

In this article, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, explores the potential of PDCs and their role in shaping the future of drug discovery.

Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients

Sign up to the Linkers System and receive email notifications

Access to new sales channels where leading manufacturers can directly access the database and engage with prospective partner companies.


What is Linkers?

Linkers is a system where SMEs, Startups and Academia can directly respond to the needs of major Japanese manufacturers.


Find out more via the hyperlink above!

Two companies, TraitSeq and PfBIO, that originated from research carried out at Norwich Research Park, have announced significant funding that will help them with the next stages of their development. Both were successful in securing grants of around £100,000 from Innovate UK’s Launchpad programme. Only seven companies in the East of England received these grants where the focus is to develop new activity in agri-tech and food technology and drive innovation in food production and sustainability.